Conference presentation
Logotype for Octave Specialty Group Inc

Octave Specialty Group (OSG) Conference presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Octave Specialty Group Inc

Conference presentation summary

17 Nov, 2026

Platform and strategy

  • Built a 22-MGA specialty platform through 17 de novo launches and 5 established MGA acquisitions; business mix is 42% casualty, 34% A&H and 24% property.

  • Operates across the U.S., London and Bermuda; Octave Ventures backs new MGA launches, while Octave Partners focuses on acquisitions and bolt-ons.

  • MGA model earns commissions and fees on premiums placed, plus profit commissions, without taking balance-sheet insurance risk; 2026E premiums placed ~ $1.3B.

  • Third-party capacity exceeds $2.0B for current business and has historically been oversubscribed; capacity figure excludes Everspan.

  • Organic growth levers include de novo launches, product and geographic expansion, cross-selling, technology, capacity partnerships and broader distribution.

Insurance distribution

  • 9M26 revenue was $195.3M, up 67% YoY; organic revenue growth was 35.5%.

  • 9M26 adjusted EBITDA to shareholders was $43.4M, with a 22.2% margin; adjusted operating margin was 31.0%, up from 22.7% in 9M25.

  • 2026E guidance: organic growth of 25%+ and adjusted EBITDA to shareholders of $45M+; segment guidance is based on updates made in August 2026.

  • De novo MGAs launched in 2024–25 drove ~60% of 9M26 organic growth; roughly half were EBITDA-positive at 3Q26. Established MGAs contributed ~40%.

  • Through 9M26, 7 U.S. product adjacencies launched; 3 additional product expansions were announced around the end of 3Q26.

Specialty P&C and Everspan

  • Everspan is a hybrid fronting carrier writing 30 programs at September 30, 2026; it cedes most risk to highly rated reinsurers and earns fronting fees and retained underwriting profit.

  • 2026E gross written premium guidance is ~ $410M and adjusted EBITDA guidance is ~ $6M, up 58% vs. $3.8M in 2025; 3Q26 GAAP book value was $129M.

  • 9M26 reported combined ratio was 115.1%; pro forma adjusted combined ratio was 96.7%, excluding litigation settlement, adverse development, severance and other items.

  • Everspan reported a 9M26 loss ratio of 70.7%, 260 bps better than 9M25; strategy includes shifting retained mix toward package and low-cat property and exiting underperforming programs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Octave Specialty Group